The Conversation (0)
Adding the the drug ganetespib to a standard chemotherapy drug could boost survival of lung cancer patients, reports US News & World Report.
Adding the the drug ganetespib to a standard chemotherapy drug could boost survival of lung cancer patients, reports US News & World Report.
As quoted in the market news:
The finding centers on a class of medications known as heat shock protein 90 (Hsp90) inhibitors, and it’s the first time in more than 10 years that researchers have uncovered a better way to treat this group of patients.
The findings were slated for presentation Monday in Chicago at the annual meeting of the American Society of Clinical Oncology.
Click here to read the full news story in US News & World Report
The news caused stock in the drug’s manufacturer, Synta Pharmaceuticals Corp (NASDAQ:SNTA) to plunge over 33 percent on Monday, reported Fierce Biotech.